Cresco Labs (CRLBF) Total Non-Current Liabilities (2019 - 2026)
Cresco Labs' (CRLBF) quarterly Total Non-Current Liabilities came in at $856.5 million in Q1 2026, down 2.15% YoY from $875.3 million in Q1 2025, and up 1.4% on a QoQ basis from $844.6 million in Q4 2025.
Cresco Labs (CRLBF) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 8 years of Total Non-Current Liabilities data on file, last reported at $856.5 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 2.15% year-over-year to $856.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $856.5 million (down 2.15% YoY) and the FY2025 annual result came in at $844.6 million, down 3.23% from the prior year.
- Total Non-Current Liabilities improved to $856.5 million in Q1 2026, from $844.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $885.5 million in Q2 2025 to a low of $689.2 million in Q2 2022.
- A 5-year average of $784.0 million and a median of $740.1 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 64.23% — and 2025, when it slipped 3.23%.
- Tracing CRLBF's Total Non-Current Liabilities over 5 years: stood at $740.1 million in 2022, then dropped by 1.35% to $730.2 million in 2023, then gained by 19.54% to $872.8 million in 2024, then dropped by 3.23% to $844.6 million in 2025, then gained by 1.4% to $856.5 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $856.5 million (Q1 2026), $844.6 million (Q4 2025), and $842.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Cresco Labs | 290.46 Mn | 226.34 Mn | 86.95 Mn | 862.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 856.48 Mn |
| Dec 31, 2025 | 844.62 Mn |
| Sep 30, 2025 | 842.79 Mn |
| Jun 30, 2025 | 885.52 Mn |
| Mar 31, 2025 | 875.34 Mn |
| Dec 31, 2024 | 872.84 Mn |
| Sep 30, 2024 | 859.00 Mn |
| Jun 30, 2024 | 846.66 Mn |
| Mar 31, 2024 | 730.94 Mn |
| Dec 31, 2023 | 730.16 Mn |
| Sep 30, 2023 | 712.41 Mn |
| Jun 30, 2023 | 726.61 Mn |
| Mar 31, 2023 | 710.63 Mn |
| Dec 31, 2022 | 740.14 Mn |
| Sep 30, 2022 | 714.28 Mn |
| Jun 30, 2022 | 689.20 Mn |
| Mar 31, 2022 | 690.00 Mn |
| Dec 31, 2021 | 694.33 Mn |
| Sep 30, 2021 | 648.42 Mn |
| Mar 31, 2021 | 420.14 Mn |